Head and Neck carcinoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient with untreated head and neck carcinoma and receiving individualized treatment regimens of Docetaxel, Cisplatin and 5FU as developed. StageI, II, III and IVA ECOG PS 1 and 2
Exclusion criteria
Exclusion criteria: Patients with hypersensitivity to levocarnitine. Patients who takes levocarnitine within one month from the present. Pregnant female and nursing female. Patient that informed concent is not provided. Patient with sereous renal failure Patient with insulin dependent diabetes mellitus, diabetic ketoacidosis and metabolic acitosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum carnitine levels include free body, acyl body and total before and after induction chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Fatigue used VAS scale before and after induction chemotherapy. Body component include body weight, volume of skeletal muscle and fat, BMI, BCM and AC% used In Body. Volume of skeletal muscle and fat used computed tomography. Clinical biochemistry and hematology include AST, ALT, ALP, Alb, T-Bil, BUN, Cr, PLT, PT(s), TP, T-Cho, Ch-E, TG, FFA, Pr-Alb, CRP, blood glucose level,RBC, WBC, Hb. | — |
Countries
Japan
Contacts
Tokyo Medical University Department of Otorhinolaryngology, Head and Neck Surgery